Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
| Autor: | Tingting Chen, Hanhui Min, Ahmed Moudud, Nasrin Aktar, Xiaoqing Gao, Meng Tang, Xiaohui Zhou |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Gabapentin Pregabalin Acupuncture Therapy Anti-Inflammatory Agents Prostatitis Pelvic Pain Chronic prostatitis/chronic pelvic pain syndrome Internal medicine Drug Discovery medicine Humans Pharmacology business.industry Pelvic pain medicine.disease Review article Sexual dysfunction cGMP-specific phosphodiesterase type 5 Chronic Disease Quality of Life medicine.symptom Chronic Pain business medicine.drug |
| Zdroj: | Current pharmaceutical design. 27(25) |
| ISSN: | 1873-4286 |
| Popis: | Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|